Understand the source comparison
Core Peptides Alternative: Research-Grade Supplier Comparison
This table compares the most commonly considered core peptides alternative options based on regulatory compliance, purity verification, and documentation practices that matter for research integrity. Real Peptides Yes. Facility inspections public Every batch s
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares the most commonly considered core peptides alternative options based on regulatory compliance, purity verification, and documentation practices that matter for research integrity.
- Real Peptides
- Yes. Facility inspections public
- Every batch sent to independent lab
- Full COA with HPLC, MS, amino acid analysis per batch
- 98.5–99.8% verified
- Meets all regulatory baselines for research use; documentation practices support IRB filings and publication standards
- Generic Overseas Suppliers
- No. Not subject to FDA oversight
- Inconsistent; often self-reported only
- Limited or absent; COAs may not match shipped product
- 85–95% claimed, unverified
- Compliance gap for US-based research; lack of chain-of-custody documentation creates audit risk
- Domestic Compounding Pharmacies (Non-503B)
- State-licensed but not 503B
- Variable; depends on pharmacy policy
- Patient-focused, not research-grade
- 95–98% typical
- Not designed for research applications; documentation doesn't support regulatory filings
- Research Chemical Vendors
- No regulatory oversight
- Rare; typically none
- No standardized COA format
- 90–97% claimed
- High variability; unsuitable for regulated research or studies requiring reproducibility